Pharma Equity Group A/S Cl A Total Liabilities
Pharma Equity Group A/S Cl A total liabilities. Based on the latest financial reports, Pharma Equity Group A/S Cl A (PEG) has total liabilities worth Dkr13.43 Million DKK (≈ $2.10 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PEG financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Pharma Equity Group A/S Cl A (2008–2025)
Total liabilities of Pharma Equity Group A/S Cl A from 2008 to 2025. This chart illustrates how Pharma Equity Group A/S Cl A's total liabilities have evolved over time, based on quarterly financial data.
Pharma Equity Group A/S Cl A Competitors by Total Liabilities
The table below lists competitors of Pharma Equity Group A/S Cl A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mixed Martial Arts Group Limited
NYSE MKT:MMA
|
USA | $5.35 Million |
|
Ateliers Mecaniques D’Indonesie Tbk PT
JK:AMIN
|
Indonesia | Rp114.00 Billion |
|
Kritika Wires Limited
NSE:KRITIKA
|
India | Rs-1.01 Billion |
|
Quanome Technologies, Inc.
NASDAQ:QNME
|
USA | $4.65 Million |
|
Perfect Moment Ltd.
NASDAQ:PMNT
|
USA | $13.98 Million |
|
Ping An Biomedical Co., Ltd.
NASDAQ:PASW
|
USA | $23.17 Million |
|
Hydrogen Refueling Solutions
PA:ALHRS
|
France | €59.31 Million |
|
HWH International Inc
NASDAQ:HWH
|
USA | $1.71 Million |
Liability Composition Analysis (2008–2025)
This chart breaks down Pharma Equity Group A/S Cl A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Pharma Equity Group A/S Cl A total assets.
Liquidity & Leverage Metrics
Pharma Equity Group A/S Cl A Total Liabilities Ratios Explained
Pharma Equity Group A/S Cl A total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pharma Equity Group A/S Cl A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pharma Equity Group A/S Cl A (2008–2025)
The table below shows the annual total liabilities of Pharma Equity Group A/S Cl A from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | Dkr13.43 Million ≈ $2.10 Million |
-19.75% |
| 2024-09-30 | Dkr16.73 Million ≈ $2.62 Million |
-60.54% |
| 2023-09-30 | Dkr42.40 Million ≈ $6.63 Million |
+69.43% |
| 2022-09-30 | Dkr25.03 Million ≈ $3.92 Million |
+18.73% |
| 2021-09-30 | Dkr21.08 Million ≈ $3.30 Million |
-9.54% |
| 2020-09-30 | Dkr23.30 Million ≈ $3.65 Million |
+70.30% |
| 2019-09-30 | Dkr13.68 Million ≈ $2.14 Million |
+318.92% |
| 2018-09-30 | Dkr3.27 Million ≈ $510.99K |
+170.14% |
| 2017-09-30 | Dkr1.21 Million ≈ $189.16K |
-95.83% |
| 2016-09-30 | Dkr28.98 Million ≈ $4.53 Million |
+8.43% |
| 2015-09-30 | Dkr26.72 Million ≈ $4.18 Million |
+2.69% |
| 2014-09-30 | Dkr26.02 Million ≈ $4.07 Million |
-92.70% |
| 2013-09-30 | Dkr356.68 Million ≈ $55.81 Million |
-23.70% |
| 2012-09-30 | Dkr467.46 Million ≈ $73.14 Million |
+9.20% |
| 2011-09-30 | Dkr428.10 Million ≈ $66.98 Million |
-3.62% |
| 2010-09-30 | Dkr444.20 Million ≈ $69.50 Million |
+1897.56% |
| 2009-09-30 | Dkr22.24 Million ≈ $3.48 Million |
-89.17% |
| 2008-09-30 | Dkr205.42 Million ≈ $32.14 Million |
-- |
About Pharma Equity Group A/S Cl A
Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which the current therapy is lacking or in need of improvement. Its products under development, includes RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment… Read more